OKLO · Oklo Inc. · Stock research

Coverage refresh. Prior note dated 2026-08-24; this advances it with the 2026-08-24 session, the lapse of the post-criticality zone, and the shift of the next company-dated event out to the Q3 print.

OKLO — Oklo Inc.

Current Thesis

The narrative leg on offer is second-order AI power: datacenter electricity demand routed through the first private US developer to take a greenfield reactor critical under the Department of Energy pilot pathway, funded by $3.0B of cash and marketable securities at 2026-06-30 against $1.210M of quarterly revenue.

What changed in the last session is the price, not the company. The 2026-08-24 close of $39.69 sits below the 2026-08-21 close of $42.09 and below the 2026-08-04 close of $43.33 — beneath where the stock traded before either the 2026-08-06 Groves first-criticality release or the 2026-08-07 Q2 print. Eleven completed sessions have now run since the print with no new company disclosure behind any of them. StockTitan's OKLO news and filings feed still carried the 2026-08-07 results release as its newest item when re-checked 2026-08-24.

The forward calendar is now bare of company events. Data providers carry the Q3 print at ~2026-11-18; between here and there the only dated items are mechanical — the FINRA short-interest reading for the 2026-08-14 settlement due ~2026-08-26, and the next monthly founder tranche under the Rule 10b5-1 plans around 2026-09-01.

Archetype. The binary-catalyst frame that carried into 2026-08-07 has resolved and lapsed; this is now classified as second-order AI power. For the fifth consecutive week the sessions have priced off long-end yields and hyperscaler-capex sentiment rather than off anything Oklo published.

The narrative is saturated. First dated 2026-08-14, re-confirmed 2026-08-18, 2026-08-20, 2026-08-21 and again on the 2026-08-24 close. Twenty-five analysts already cover the name, the 2026-08-23 Motley Fool piece moved retail-facing coverage off the milestone and onto the 2028 revenue schedule, and the price is 77.2% below the $174.14 52-week high on the adjusted series. Two consecutive favourable disclosures failed to hold a bid, which points to thin new demand rather than fresh attention.

Bullish and bearish views on Oklo Inc.

The model's bull view on Oklo Inc. (OKLO), in brief: Groves reached first criticality on 2026-08-06, 229 days after substantial construction completion — an operating step no other US private microreactor developer has taken. The bear view: Eleven completed sessions since 2026-08-07 with no company disclosure, ending at the 2026-08-24 close of $39.69 — below the pre-news 2026-08-04 close of $43.33. Both cases follow in full.

Bull Case

• Groves reached first criticality on 2026-08-06, 229 days after substantial construction completion — an operating step no other US private microreactor developer has taken.
• Revenue is booked rather than modelled: $1.210M in Q2 2026 against a $126,250 consensus (2026-08-07 release).
• Cash and marketable securities of $3.0B at 2026-06-30 ($1.6B cash, $1.4B securities) versus $2.54B at 2026-03-31, throwing off $44.5M of H1 interest and dividend income against an H1 net loss of $81.6M. Funding is not the near-term binding constraint.
• Four dated DOE-pathway steps cleared in ten weeks: Aurora-INL Preliminary Documented Safety Analysis 2026-06-11, Groves final safety analysis 2026-07-01, Groves startup authorization 2026-07-23, first criticality 2026-08-06.
• Commercial anchors named on the 2026-08-07 call: a long-term Meta power commitment supporting phased Aurora deployments, and a Centrus letter of intent dated 2026-06-18 covering domestic HALEU.
• Sell-side marks sit far above the tape even after four reductions: 25-analyst consensus $79.88, HC Wainwright Buy at $90 (2026-08-10), Canaccord Buy at a reduced $100 (2026-08-10), Texas Capital Buy at $89 (2026-08-20).

Bear Case

• Eleven completed sessions since 2026-08-07 with no company disclosure, ending at the 2026-08-24 close of $39.69 — below the pre-news 2026-08-04 close of $43.33.
• Every published sell-side revision since the print has been downward: Canaccord $125 to $100, Citigroup $76 to $57.50, Truist $55 to $51 (all 2026-08-10), Texas Capital $93 to $89 (2026-08-20). Investing.com's 12-month range as of 2026-08-24 spans $14 to $130 around the $79.88 mean — a dispersion that says the analyst set has no shared model.
• The dated revenue schedule is long. Management said on the 2026-08-07 call that first isotope revenue is more likely to come from the NRC-licensed Idaho Radiochemistry Laboratory than from Groves, in the first part of 2027; commercial HALEU from Centrus is not expected until 2029 under the current letter of intent; the 2026-08-23 Motley Fool write-up put commercial power revenue no earlier than 2028.
• FY2026 guides of $120-150M operating cash use and $400-500M capex were set alongside the print, and a $1.0B at-the-market equity programme has been live since the 2026-05-13 424B5 — strength can be met with issuance without any new announcement.
• Insider supply runs on a calendar, not a news cycle. Form 4s for 2026-08-03 under Rule 10b5-1 plans show CEO Jacob DeWitte selling 40,000 Class A shares at $41.68 direct plus GRAT dispositions of 12,849 at $40.14 and 7,151 at $40.94, and Caroline Cochran selling 40,000 at $41.35 indirect plus 16,500 at $38.55 and 3,500 at $39.60. The next tranche lands on the same monthly cadence around 2026-09-01.
• Market capitalisation of $7.38B on 186.02M shares outstanding (stockanalysis.com, 2026-08-24) against $1.210M of quarterly revenue means conventional earnings and sales multiples carry no information here; the entire mark is schedule adherence.

Setup & Price Structure

• Reference close 2026-08-24: $39.69. That is 77.2% beneath the $174.14 52-week high on the adjusted daily series, with a three-month price change of -42.2%.
• RSI(14) at 43.5 on that close. Eleven sessions of decline off the post-print zone have not produced an oversold reading, so momentum is drifting rather than flushing.
• $36.61 is the 52-week low, set in the 2026-07-29 window. $38.83 marks the level that hands back the entire three-session recovery that ran off that low into the 2026-08-04 close of $43.33; a close beneath it returns the low to the tape as the nearest reference.
• $43.33 is the reclaim level. Neither the 2026-08-06 criticality release nor the 2026-08-07 print produced a close above it, which is what dates the saturated read rather than a maturing one.
• 25 sell-side analysts on the name with a $116 spread between the high and low targets; monthly founder 10b5-1 supply with Form 4s typically filed within two business days; a $1.0B ATM standing undrawn as far as disclosure shows; and no earnings date inside the next 30 days.
• The Section 16 group widened on 2026-07-27 and five newly elevated executive officers filed initial Form 3s on 2026-08-04, which broadens the pool of future insider filings independently of any change in intent.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — FINRA semi-monthly short interest for the 2026-08-14 settlement.
• ~2026-09-01 (est.) — Next monthly founder tranche under the Rule 10b5-1 plans adopted 2025-03-31, on the 2026-06-01 / 2026-07-01 / 2026-08-03 cadence.
• ~2026-09-10 (est.) — FINRA short interest for the 2026-08-31 settlement, the first reading with the entire post-print range inside it.
• ~2026-09-23 (est.) — Nothing company-dated is scheduled through the end of this window. The next Oklo-controlled disclosure on the calendar is the Q3 print at ~2026-11-18 (est.), which leaves the name trading on rates and theme flow until then.

What Would Change Our Mind

The structure that matters is the three-session recovery off the 2026-07-29 low, which is what stands between the current tape and the $36.61 52-week low. A daily close below $38.83 gives that back and re-dates the whole 2026-06 to 2026-08 milestone run as a failed rally; the saturated label would then be describing a broken structure rather than a tired one.

On the other side, the read is wrong if the schedule pulls forward. A docketed commercial licensing step for Aurora-INL, a definitive Centrus HALEU supply agreement replacing the 2026-06-18 letter of intent, or a dated first-power or first-isotope-revenue commitment inside 2027 would each put a company-controlled event back on a calendar that currently has none before ~2026-11-18. Reclaiming and holding the 2026-08-04 close of $43.33 would show the post-criticality supply had been absorbed.

The positioning data can also flip the read: a 2026-08-26 or 2026-09-10 FINRA reading showing the ~20%-of-float short book materially reduced would mean the good news was covered into. A reading showing it larger again says the opposite. An ATM drawdown disclosed against the $1.0B programme, or open-market Form 4 sales outside the 10b5-1 cadence, would each argue the supply side is worse than the calendar implies.

Correlation Notes

• The name has traded as a rates asset for five weeks. Long-end Treasury yields snapped back toward 20-month highs on 2026-08-20 (Benzinga market wrap); Oklo's entire mark is cash flows dated 2028 and later, so duration sensitivity dominates single-stock news.
• It moves with the pre-commercial nuclear cohort — three cohort-driven sessions carried it from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04 with no Oklo release behind any of them, and that mechanism is now working in reverse.
• Second-order exposure to hyperscaler capex sentiment: the 2026-08-07 ETF coverage of the AI-power theme, and the Meta power commitment, tie the story to datacenter buildout headlines rather than to utility fundamentals.
• A priced Holtec listing under HNUC (S-1 filed 2026-07-10, estimated $2.0B raise, no price range set as of 2026-08-24) would put a revenue-generating nuclear comparable in front of the same allocators.
• Uranium and enrichment names — Centrus in particular, as the named HALEU counterparty — share headline drivers but not the licensing timeline; the linkage there is thematic until a definitive supply agreement exists.